Harrow (HROW) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
The annual meeting is scheduled for June 18, 2026, with voting on director elections, executive compensation, and auditor ratification.
The company emphasizes strong governance, independent oversight, and alignment of executive incentives with long-term shareholder value.
The proxy statement reflects expanded disclosure requirements as the company is now a large accelerated filer.
Forward-looking statements highlight ongoing risks related to business operations, regulatory matters, and cybersecurity.
Voting matters and shareholder proposals
Shareholders will vote on electing four directors, an advisory say-on-pay for executive compensation, and ratification of Deloitte & Touche LLP as independent auditor for 2026.
The board recommends voting FOR all proposals, citing director expertise, pay-for-performance alignment, and auditor qualifications.
Shareholder proposals for the 2027 meeting must be submitted by December 25, 2026, to be considered for inclusion.
Board of directors and corporate governance
The board consists of four directors, three of whom are independent; all committees are fully independent.
The board combines the roles of CEO and Chairman, with a Lead Independent Director to ensure independent oversight.
Committees include Audit, Compensation, and Nomination & Corporate Governance, each chaired by an independent director.
Directors possess a balanced mix of executive, financial, industry, and governance experience.
The board maintains a Code of Business Conduct and Ethics and an insider trading policy prohibiting short sales, pledging, and hedging without approval.
Latest events from Harrow
- Key votes on directors, executive pay, and auditor set for June 2026 annual meeting.HROW
Proxy filing25 Apr 2026 - Double-digit growth and expanding ophthalmic launches drive strong future outlook.HROW
Leerink Global Healthcare Conference 202610 Mar 2026 - Record 36% revenue growth in 2025 sets up $350M–$365M guidance and strong momentum for 2026.HROW
Q4 20253 Mar 2026 - Q2 2024 revenue up 46% on IHEEZO and VEVYE growth; strong outlook for 2024.HROW
Q2 20242 Feb 2026 - Rapid revenue growth and new product launches position the company for strong future expansion.HROW
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026 - VEVYE, IHEEZO, and Triessence drive growth toward a $1B revenue target by 2027.HROW
2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026 - Q3 2024 revenue up 44–46% year-over-year, with strong product launches and robust outlook.HROW
Q3 202414 Jan 2026 - Prescription innovation and targeted launches drive growth, with MELT-300 as a major future catalyst.HROW
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Record revenue, margin gains, and strong outlook fueled by branded product growth.HROW
Q4 202426 Dec 2025